Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04332926 · ClinicalTrials.gov registry record · NA

Effects of E-Cigarette Nicotine Content in Smokers (Nicotine Flux Study)

A NA study, sponsored by Virginia Commonwealth University.

Completed
Registry status
NA
Development phase
44
Enrollment target

NCT04332926 is a NA study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 44 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04332926, a NA study, has completed, sponsored by Virginia Commonwealth University.

COMPLETED
Registry status
NA
Development phase
44 participants
Enrollment target

Study Summary

This study aims to better understand how e-cigarettes (ECIG) nicotine flux impacts several behavioral economic measures of abuse liability.

Interventions

  • OTHER Tobacco product administration and assessment, own brand cigarettes
  • OTHER Tobacco product administration and assessment, ECIG 30 Watts, 0 mg/ml nicotine
  • OTHER Tobacco product administration and assessment, ECIG 30 Watts, 8 mg/ml nicotine
  • OTHER Tobacco product administration and assessment, ECIG 30 Watts, 15 mg/ml nicotine
  • OTHER Tobacco product administration and assessment, ECIG 30 Watts, 30 mg/ml nicotine

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2021-01-05
Est. Completion 2023-09-08
Phase NA

Sponsor

Virginia Commonwealth University

558 total trials

What the Registry Record Tells You About NCT04332926

The ClinicalTrials.gov registry entry for NCT04332926 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which Tobacco product administration and assessment, own brand cigarettes is the first listed.

NCT04332926 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04332926 about?

NCT04332926 is a clinical study titled "Effects of E-Cigarette Nicotine Content in Smokers (Nicotine Flux Study)". This study aims to better understand how e-cigarettes (ECIG) nicotine flux impacts several behavioral economic measures of abuse liability.

What is the current status of trial NCT04332926?

This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2021-01-05. Estimated completion is 2023-09-08.

What interventions are being tested in trial NCT04332926?

The interventions under investigation include: Tobacco product administration and assessment, own brand cigarettes (OTHER), Tobacco product administration and assessment, ECIG 30 Watts, 0 mg/ml nicotine (OTHER), Tobacco product administration and assessment, ECIG 30 Watts, 8 mg/ml nicotine (OTHER), Tobacco product administration and assessment, ECIG 30 Watts, 15 mg/ml nicotine (OTHER), Tobacco product administration and assessment, ECIG 30 Watts, 30 mg/ml nicotine (OTHER).

Who is sponsoring clinical trial NCT04332926?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.